Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $14.56 and last traded at $14.05, with a volume of 97000 shares traded. The stock had previously closed at $13.95.
Several equities research analysts have issued reports on EIGR shares. Oppenheimer set a $34.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. Ladenburg Thalmann Financial Services started coverage on Eiger Biopharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $32.00 price objective for the company. Finally, ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $30.63.
The company has a quick ratio of 5.78, a current ratio of 5.78 and a debt-to-equity ratio of 1.19. The firm has a market cap of $154.59, a PE ratio of -2.74 and a beta of 2.54.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Wedbush Securities Inc. acquired a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $114,000. Susquehanna International Group LLP acquired a new position in Eiger Biopharmaceuticals during the second quarter valued at approximately $114,000. Bank of New York Mellon Corp boosted its position in Eiger Biopharmaceuticals by 6.4% during the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 871 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 8,748 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $147,000. 47.06% of the stock is owned by hedge funds and other institutional investors.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.